KSB Limited (BOM:500249)

CTI BioPharma Balance Sheet

Financials in millions INR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,167	959.01	1,195	319.34	565.65	870.68
Short-Term Investments	-	2,268	1,543	1,265	1,835	2,696
Cash & Short-Term Investments	3,167	3,227	2,738	1,584	2,401	3,567
Cash Growth	-18.19%	17.85%	72.87%	-34.03%	-32.69%	44.69%
Accounts Receivable	6,856	6,503	4,917	4,037	2,780	2,668
Other Receivables	-	94.36	63.41	89.94	100.28	96.24
Receivables	6,899	6,650	5,009	4,166	2,907	2,783
Inventory	7,412	6,428	6,426	5,611	4,231	3,609
Prepaid Expenses	-	32.45	23.69	17.79	10.9	12.14
Other Current Assets	1,002	699.36	464.52	1,359	1,652	941.93
Total Current Assets	18,480	17,037	14,661	12,738	11,202	10,912
Property, Plant & Equipment	4,842	4,720	4,290	3,735	3,485	3,421
Long-Term Investments	883	878.28	795.36	63.15	697.48	662.32
Other Intangible Assets	219	211.2	223.99	17.05	13.41	13.71
Long-Term Accounts Receivable	19	19.14	42.34	98.24	145.36	166.41
Long-Term Deferred Tax Assets	-	-	-	166.85	51.1	8.93
Other Long-Term Assets	541	534.33	570.58	825.17	415.86	135.31
Total Assets	25,058	23,480	20,657	17,735	16,094	15,402
Accounts Payable	4,259	3,753	3,433	3,143	2,792	2,628
Accrued Expenses	-	1,195	1,098	800.74	820.88	801.02
Short-Term Debt	-	-	-	-	-	600
Current Portion of Leases	12	12.69	11.34	9.31	9.55	6.76
Current Income Taxes Payable	53	74.7	-	-	17.64	184.38
Other Current Liabilities	4,692	2,977	2,623	2,399	1,809	1,813
Total Current Liabilities	9,016	8,012	7,165	6,351	5,448	6,033
Long-Term Leases	34	21.67	21.02	19.51	20.34	8.98
Long-Term Deferred Tax Liabilities	17	22.83	15.4	-	-	-
Other Long-Term Liabilities	647	125.82	97.87	77.17	34.07	26.24
Total Liabilities	9,714	8,627	7,638	6,804	5,985	6,496
Common Stock	348	348.08	348.08	348.08	348.08	348.08
Additional Paid-In Capital	-	3.2	3.2	3.2	3.2	3.2
Retained Earnings	-	14,502	12,668	10,579	9,757	8,555
Comprehensive Income & Other	14,996	0.25	0.25	0.25	0.25	0.25
Shareholders' Equity	15,344	14,854	13,019	10,931	10,108	8,906
Total Liabilities & Equity	25,058	23,480	20,657	17,735	16,094	15,402
Total Debt	46	34.36	32.36	28.82	29.89	615.74
Net Cash (Debt)	3,121	3,193	2,706	1,555	2,371	2,951
Net Cash Growth	-18.81%	17.99%	73.99%	-34.41%	-19.66%	58.23%
Net Cash Per Share	17.94	18.34	15.55	8.94	13.62	16.96
Filing Date Shares Outstanding	174.26	174.04	174.04	174.04	174.04	174.04
Total Common Shares Outstanding	174.26	174.04	174.04	174.04	174.04	174.04
Working Capital	9,464	9,025	7,496	6,386	5,754	4,879
Book Value Per Share	88.05	85.35	74.81	62.81	58.08	51.17
Tangible Book Value	15,125	14,642	12,795	10,914	10,095	8,892
Tangible Book Value Per Share	86.80	84.13	73.52	62.71	58.00	51.09
Land	-	3.01	3.01	3.01	3.01	3.01
Buildings	-	2,755	2,625	2,299	2,022	1,990
Machinery	-	6,399	5,969	5,479	4,975	4,797
Construction In Progress	-	528.08	310.25	251.43	391.76	251

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.